<DOC>
	<DOCNO>NCT00446667</DOCNO>
	<brief_summary>COPD major cause ill health death Australia 40,000 hospital admission , national cost $ 898,000,000 annually . The gold standard treatment COPD steroid inflammation , antibiotic infection bronchodilator oxygen respiratory failure . However , associate mucus hypersecretion responsible much inflammation infection . The use pharmaceutical agent assist early clearance retain mucus limited , primarily lack demonstrated effect . There recent development interest pursue new therapy improve mucociliary clearance several study demonstrate clinical outcome improve osmotic agent mannitol add standard treatment . The purpose study conduct pilot safety study patient acute exacerbation COPD determine safe administer inhale mannitol facilitating mucus clearance .</brief_summary>
	<brief_title>A Pilot Safety Study Inhaled Dry Powder Mannitol Acute Exacerbations COPD</brief_title>
	<detailed_description />
	<mesh_term>Mannitol</mesh_term>
	<criteria>FEV1 &gt; 35 % predict COPD Exacerbation Inpatient Pneumonia CO2 retention</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>